enGene Therapeutics Inc. ENGN
1.85 USD +0.13 (+7.56%)
Regular-session close
1.85 0.00 0.00%
After hours · Nov 18, 4:40 PM ET
1.65 Day range 1.95
1.40 52-week range 12.25
- YTD
- -79.51%
- 1 year
- -73.11%
News
seekingalpha.com enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded AMD, Reliance, enGene, Mid Penn Bancorp and Republic Services, raising price targets for RS and MPB.benzinga.com Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4 Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.
benzinga.com Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6 Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
businesswire.com enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the…
businesswire.com enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of…
businesswire.com enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
defenseworld.net enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings…
marketbeat.com enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse,…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
businesswire.com enGene to Host KOL Webinar on October 15, 2026 BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk…
businesswire.com enGene Reports Third Quarter 2026 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results…
businesswire.com enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
defenseworld.net Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN) enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies…
marketbeat.com enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
businesswire.com enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
businesswire.com enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of…
globenewswire.com Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to…
businesswire.com enGene Reports Second Quarter 2026 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for…
